生产厂家英文名：Meiji Seika Pharma
原产地英文商品名：LASERPHYRIN FOR INJECTION （注射用レザフィリン）100mg/vial
商标名：LASERPHYRIN 100mg FOR INJECTION
本产品是吸湿一般名タラポルフィンナトリウム Talaporfin Sodium
构造式融 点：約150℃（分解点）分配係数（log10 1-オクタノール層／水層）（下表参照）pH2pH4pH6pH8～12＞3.002.08－1.58＜－3.00条件批准在建立药品风险管理计划的顶部，要正确实施。
2.原发性恶性脑肿瘤通常，成人为40mg/ m 2至单次静脉内注射。静脉内注射22-26小时后的激光照射到病变部位。
Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.Brand name : LASERPHYRIN 100mg FOR INJECTION Active ingredient: Talaporfin sodium Dosage form: injection Print on wrapping:Effects of this medicineThis medicine gathers in and around tumor cells and reacts to laser light to exert an antitumor effect.It is usually used to treat early-stage lung cancer, primary malignant brain tumor (only when surgical removal of the tumor is performed) and local failure after chemoradiotherapy or radiotherapy for esophageal cancer eligible for laser irradiation. Thus, this is a local treatment and is ineffective on non-irradiated laser site.Before using this medicine, be sure to tell your doctor and pharmacist•If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.If you have porphyria.•If you are pregnant or breastfeeding.•If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)Dosing schedule (How to take this medicine)•Your dosing schedule prescribed by your doctor is <<to be written by a healthcare professional>>•Early-stage lung cancer, local failure after chemoradiotherapy or radiotherapy for esophageal cancer: In general, this medicine is injected once intravenously. The target lesion is then irradiated by laser light 4 to 6 hours after the injection.Primary malignant brain tumor: In general, this medicine is injected once intravenously. The target lesion is then irradiated by laser light 22 to 26 hours after the injection.•The treatment period with this medicine is determined based on the response to the treatment. Ask the doctor about the treatment span.Precautions while taking this medicine•In treatment of local failure in patients with esophageal cancer, dietary intake may cause intense inflammation and weakening of the tissues, resulting in esophageal perforation. For this reason, the patients should fast from the morning on the day of administration until the following day of laser irradiation and receive nutritional care with fluid replacement.•This medicine may cause photosensitivity. Avoid direct sunlight and stay in rooms conditioned at lighting intensity of 500 lux or less by using shade curtains for 2 weeks after the injection. Wear sunglasses for 3 days after the injection.Possible adverse reactions to this medicineThe most commonly reported adverse reactions include increased sputum, bloody sputum, cough, sore throat, fever and esophageal pain. If any of these symptoms occur, consult with your doctor or pharmacist.The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.•breathing difficulty, shortness of breath on exertion [respiratory distress]•general malaise, loss of appetite, yellowing of the skin and the white of eyes [liver dysfunction]Meiji Seika Pharma Co., Ltd.InjectionRevised: 8/2015The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.Advantages of laserphyrin compared with photofrin in photodynamic therapy for bile duct carcinomaAbstractBackgroundThe aim of this study was to compare the effects of laserphyrin-PDT (L-PDT) on biliary cancer with those of the conventional photosensitizer, photofrin-PDT (P-PDT).MethodsAn animal tumor model was established by inoculation of NOZ cells in 4-week-old male BALB/c mice. The laser light wavelength was set at 630 nm for P-PDT and 660 nm for L-PDT, at a frequency of 10 Hz. Each group received a total energy flux of 60 J/cm2. The proportion of TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling)-positive cells, expression of VEGF (vascular endothelial growth factor) and the PCNA (proliferating cell nuclear antigen)-labeling index (LI) were assessed after PDT.ResultsL-PDT had significantly more potent apoptotic effects at 48 and 72 h after light exposure compared with P-PDT (P < 0.001). The mean PCNA-LI was significantly lower in the L-PDT group than the P-PDT group and the index was significantly lower at several time points after PDT (6, 12, 24, 48 and 72 h after laser light exposure) in the L-PDT than P-PDT (P < 0.001 vs. control). The cell proliferative activity was significantly decreased at 12 and 24 h after P-PDT compared with the control (P < 0.001). VEGF expression was significantly higher at 3 h after L-PDT compared with the control (P < 0.05), whereas it was significantly higher at many time points after P-PDT (3, 6, 48 and 72 h; P < 0.05 vs. control).ConclusionsL-PDT is a better approach for biliary cancer than the conventional P-PDT, based on its potent apoptotic and cytostatic effects.